Fred Aslan - 19 May 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ARTV
Reported as of: 19 May 2026
Net transaction value: -$244,253
SEC form: 4
Accepted by SEC: 19 May 2026, 21:50:02 UTC
Prior SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew Cronauer, Attorney-in-Fact

Key filing fact

Fred Aslan filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 19 May 2026.

Key facts

This page summarizes Fred Aslan's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 21:50.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: -$244,253.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001909362 Primary reporting owner

Aslan Fred

Relationship: Chief Executive Officer, Director
Address: C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
Signature: /s/ Andrew Cronauer, Attorney-in-Fact
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARTV transaction

Common Stock

Sale

Transaction value: $244,253
Shares: -27,116
Change %: -1.7%
Price: $9.01
Shares after: 1,535,082
Date: 19 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Footnote F2

The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.